The Lung Microbiome in Idiopathic Pulmonary Fibrosis: A Promising Approach for Targeted Therapies

This review focuses on the role of the lung microbiome in idiopathic pulmonary fibrosis. Although historically considered sterile, bacterial communities have now been well documented in lungs both in healthy and pathological conditions. Studies in idiopathic pulmonary fibrosis (IPF) suggest that inc...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2017-12, Vol.18 (12), p.2735
Main Authors: Fastrès, Aline, Felice, Florence, Roels, Elodie, Moermans, Catherine, Corhay, Jean-Louis, Bureau, Fabrice, Louis, Renaud, Clercx, Cécile, Guiot, Julien
Format: Article
Language:English
Subjects:
Antibiotics
Bacteria
Cardiovascular & respiratory systems
Disease Progression
Fibrosis
Gastroesophageal reflux
Human health sciences
Humans
idiopathic pulmonary fibrosis
Idiopathic Pulmonary Fibrosis - microbiology
Idiopathic Pulmonary Fibrosis - pathology
Immune system
Immunization
Innate immunity
interstitial lung diseases
Life sciences
Lung - microbiology
Lung - pathology
Lung diseases
Lung Diseases, Interstitial - microbiology
Lung Diseases, Interstitial - pathology
Lungs
Microbiologie
Microbiology
microbiome
Microbiomes
microbiota
Microbiota - physiology
Pathogenesis
Pulmonary fibrosis
Review
Sciences de la santé humaine
Sciences du vivant
Systèmes cardiovasculaire & respiratoire
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This review focuses on the role of the lung microbiome in idiopathic pulmonary fibrosis. Although historically considered sterile, bacterial communities have now been well documented in lungs both in healthy and pathological conditions. Studies in idiopathic pulmonary fibrosis (IPF) suggest that increased bacterial burden and/or abundance of potentially pathogenic bacteria may drive disease progression, acute exacerbations, and mortality. More recent work has highlighted the interaction between the lung microbiome and the innate immune system in IPF, strengthening the argument for the role of both host and environment interaction in disease pathogenesis. Existing published data suggesting that the lung microbiome may represent a therapeutic target, via antibiotic administration, immunization against pathogenic organisms, or treatment directed at gastroesophageal reflux. Taken altogether, published literature suggests that the lung microbiome might serve in the future as a prognostic biomarker, a therapeutic target, and/or provide an explanation for disease pathogenesis in IPF.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms18122735